On March 30th local time, Eli Lilly announced that its RNA therapy drug lepodisiran achieved positive results in a phase II trial. The therapy is designed to reduce the level of lipoprotein (a) production. Lipoprotein(a) is an inherited risk factor for heart disease. The Phase II trial met its primary endpoint: lepodisiran significantly reduced lipoprotein (a) levels by an average of 93.9% within 60 to 180 days after treatment with the highest dose tested (400 mg), meeting the primary endpoint. During the same period, subjects who received 16 mg and 96 mg of lepodisiran had a 40.8% and 75.2% reduction in lipoprotein(a) levels, respectively. All three dose groups tested of lepodisiran demonstrated reductions in lipoprotein(a) levels after either a single or two doses at all evaluated time points in the nearly 18-month study, meeting an additional secondary endpoint. The potential efficacy of lepodisiran will be further verified in the ongoing Phase III cardiovascular outcomes trial.